Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma
The study will utilize both retrospective and prospective data collection from patients that already had a bronchoscopy and lung resection or will have a bronchoscopy and lung resection for squamous cell carcinoma. The investigators plan to prospectively collect 5 bronchoscopic biopsies, 10ml blood and one tumor and adjacent normal samples from 200 qualified patients who meet the study criteria.
Checked against the public recordLast updated Oct 14, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Mayo Clinic
- Interventions being studied
- Genetic: DNA Extraction
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * known or suspected squamous cell carcinoma of the lung * able to provide consent * could have already had a bronchoscopy or surgical resection with tissue saved at the Mayo Clinic Rochester * will be undergoing a bronchoscopy and having a surgical resection at the Mayo Clinic Rochester Exclusion Criteria: * unable to provide consent * pregnant
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Mayo Clinic in RochesterRochester, Minnesota
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 14, 2025. Always confirm current availability with the study team.